The latest new contracts, like Myriad Genetics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
MD Anderson and Myriad Genetics Partner to Evaluate Clinical Utility of Molecular Residual Disease Assay
Jan 07, 2025•over 1 year ago
Contract Type
partnership
Salt Lake CityBiotechnologyHealth CareMedical
Description
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. have announced a strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. The alliance aims to create studies to evaluate the clinical validity and utility of Myriad’s Precise MRD.
Company Information
Company
Myriad Genetics
Location
322 North 2200 West
Salt Lake City, Utah, United States
About
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.
Salt Lake CityBiotechnologyHealth CareMedical